Graphite Bio Investor Relations Material
Latest events
M&A Announcement
Graphite Bio
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Graphite Bio Inc
Access all reports
Graphite Bio, Inc., a clinical-stage gene editing company, engages in developing therapies for diseases, primarily focused on therapies for serious and life-threatening diseases, in the United States. The company develops TALEN gene editing system for the treatment of various human diseases, including cancers. It is also involved in developing electroporation technology for drug and gene delivery.
Latest articles
)
Lowe's Companies: Building a One-Stop Shop for Home Improvement
Lowe's Companies began as a single store in 1921 and has steadily expanded its footprint and offerings, now operating 1,750 stores across the U.S.
7 May 2025
)
Greg Abel: Succeeding Warren Buffett at Berkshire Hathaway
After decades working with Warren Buffett and Charlie Munger, Greg Abel was named Buffett’s successor as he steps down in late 2025.
5 May 2025
)
Intuitive Surgical: Enhancing Surgery with Robotic Precision
Intuitive Surgical has revolutionized surgery with robotics, building its dominant position through decades of innovation, validation, and expansion.
2 May 2025
Ticker symbol
GRPH
Country
🇺🇸 United States